Literature DB >> 3619418

Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.

G L Drusano, M Weir, A Forrest, K Plaisance, T Emm, H C Standiford.   

Abstract

We examined the pharmacokinetic behavior of 200 mg of ciprofloxacin administered intravenously to 32 volunteers whose renal function as measured by creatinine clearance ranged from 0 to 8.99 liters/h per 1.73 m2. Serum clearances (mean +/- standard deviation) were 26.8 +/- 5.7 and 15.4 +/- 4.3 liters/h per 1.73 m2 in normal and anephric volunteers, respectively. The half-life (mean +/- standard deviation) increased from 4.3 +/- 0.8 h in normal volunteers to 8.6 +/- 3.3 h in anephric volunteers. There was good correlation between normalized creatinine clearance and both normalized serum and renal clearance. The regression equation for serum clearance (CLS) versus creatinine clearance (CLCR) was CLS = 1.97 X CLCR + 13.23, where r = 0.697; for renal clearance versus creatinine clearance, the equation was CLR = 2.26 X CLCR, where r = 0.845. On the basis of these data, we recommend a maximum 50% reduction in dose when ciprofloxacin is instituted at a renal function of 1.2 to 1.8 liters/h per 1.73 m2 (20 to 30 ml/min per 1.73 m2). Because of the observed variation in ciprofloxacin half-life in our anephric volunteers, we also recommend that a schedule of administration every 12 h be maintained, even for patients without urine output.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619418      PMCID: PMC284200          DOI: 10.1128/AAC.31.6.860

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Absolute oral bioavailability of ciprofloxacin.

Authors:  G L Drusano; H C Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Dose ranging study and constant infusion evaluation of ciprofloxacin.

Authors:  G L Drusano; K I Plaisance; A Forrest; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

4.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  The pharmacokinetics of ciprofloxacin in patients with impaired renal function.

Authors:  J Boelaert; Y Valcke; M Schurgers; R Daneels; M Rosseneu; M T Rosseel; M G Bogaert
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

6.  Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.

Authors:  I Shalit; R B Greenwood; M I Marks; J A Pederson; D L Frederick
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

  6 in total
  25 in total

1.  Influence of renal failure on intestinal clearance of ciprofloxacin in rats.

Authors:  S Dautrey; L Rabbaa; D Laouari; B Lacour; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.

Authors:  Elisa Borella; Italo Poggesi; Paolo Magni
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

6.  Relationships between renal function and disposition of oral ciprofloxacin.

Authors:  A Forrest; M Weir; K I Plaisance; G L Drusano; J Leslie; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

7.  Effect of renal function on the bioavailability of ciprofloxacin.

Authors:  K I Plaisance; G L Drusano; A Forrest; M R Weir; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).

Authors:  M C Vos; H H Vincent; E P Yzerman
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.